Business Description
TenNor Therapeutics, founded in 2012 and based in Suzhou, China, researches and develops medicines that target bacterial infections and related metabolic conditions. Its most advanced treatments include Rifasutenizole for stomach bacteria linked to ulcers, and Rifaquizinone, which is being studied in both injectable and oral forms for joint infections, serious skin infections, and gut disorders such as hepatic encephalopathy and irritable bowel syndrome. The company also has several earlier-stage compounds in development aimed at drug-resistant bacteria, lung infections caused by nontuberculous mycobacteria, and metabolic disease.
